However, in concordance with our results, Krishnan et al., investigating a similar percentage of strongly Ezrin‐positive EwS samples in a smaller cohort (20/25, 80%), found no significant differences in the ‘ezrin score’ of patients with localized versus metastatic disease (Krishnan et al., 2006). The gene discussed is EZR; the disease is metastatic neoplasm.